Reactive oxygen species in cancer: a paradox between pro- and anti-tumour activities Romina KohanAlejandro CollinGabriela Picotto Review Article 22 June 2020 Pages: 1 - 13
Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate Kathleen DekeisterPierre-Adrien BolzeBenoit You Original Article 04 June 2020 Pages: 15 - 24
Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia Rikke Hebo LarsenLisa Lyngsie HjalgrimJacob Nersting Original Article 09 June 2020 Pages: 25 - 32
YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects Yongxia ZhuZhihao LiuYue Wang Original Article 09 June 2020 Pages: 33 - 43
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine Xandra García-GonzálezBartosz KaczmarczykLuis A. López-Fernández Original Article 11 June 2020 Pages: 45 - 54
Influences of preoperative metformin on immunological factors in early breast cancer Takahiro TsukiokiTadahiko ShienShinichi Toyooka Original Article Open access 12 June 2020 Pages: 55 - 63
Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis Yanjiao YiZining LiuBao Song Original Article 12 June 2020 Pages: 65 - 74
C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma Go NoguchiNoboru NakaigawaMasahiro Yao Original Article 14 June 2020 Pages: 75 - 85
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach Ken OgasawaraPatricia M. LoRussoGopal Krishna Original Article 14 June 2020 Pages: 87 - 95
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors Mats NågårdMei-Lin Ah-SeeGanesh Mugundu Original Article Open access 16 June 2020 Pages: 97 - 108
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer Hossein TaghizadehMatthias UnseldGerald W. Prager Original Article Open access 18 June 2020 Pages: 109 - 115
A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703) Shin-ichi FukumotoSatoshi Oizumithe Hokkaido Lung Cancer Clinical Study Group Original Article 20 June 2020 Pages: 117 - 127
Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study Satoshi NodaDaiki HiraTomohiro Terada Original Article 25 June 2020 Pages: 129 - 139
Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study Loek A. W. de JongFortuné M. K. ElekonawoNielka P. van Erp Original Article Open access 27 June 2020 Pages: 141 - 150
Berberine chloride suppresses non-small cell lung cancer by deregulating Sin3A/TOP2B pathway in vitro and in vivo Jian ChenXiaofei HuangZhengzhi Wu Original Article 30 June 2020 Pages: 151 - 161
Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization R. B. VerheijenE. L. SwartN. Steeghs Correction 11 June 2020 Pages: 163 - 163